

Hepatitis B Vaccine Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

Market Report | 2025-07-29 | 350 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4949.00
- Five User License \$5949.00
- Corporate License \$6969.00

Report description:

The hepatitis B vaccine market size in the 7 major markets was valued at USD 4.80 Billion in 2024 , driven by the increasing incidence of hepatitis B cases across the major markets. The market is expected to grow at a CAGR of 4.80% during the forecast period of 2025-2034, with the values likely to rise to USD 7.67 Billion by 2034 .

Hepatitis B Vaccine: Introduction

Hepatitis B is a liver infection caused by the hepatitis B virus. The infection may be long term (chronic) or short term (acute). Chronic hepatitis B can put people at the risk of death from cirrhosis and liver cancer. It can spread through fluid transfusion from an infected person and even transfer from a mother to the child. Hepatitis B vaccinations play a crucial role in minimizing the risk of this fatal disease. The vaccinations can protect against the infection for at least 20 years.

Hepatitis B Vaccine Market Analysis

With notable advancements within the range vaccines available, the hepatitis B vaccine market value has risen significantly in the recent years. Some of the notable authorized hepatitis B vaccinations include Engerix-B, a noninfectious recombinant DNA vaccine, Heplisav-B, Recombivax HB, and Twinrix hepatitis vaccine, which is indicated for both hepatitis A and B, adding versatility to the market.

The hepatitis B vaccine market growth is likely to expediate with the on-going investigations. The U.S. CDC's initiative for Universal Hepatitis B Vaccination in Adults aged 19-59 signals a broader adoption trend. VTP-300, the hepatitis B vaccination by Vaccitech is undergoing trials and has shown positive outcomes, indicating its breakthrough in upcoming years.

GSK plc's upcoming presentation at The Liver Meeting 2023 is set to unveil insights from the B-Together phase IIb trial on

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

bepirovirsen. It is an antisense oligonucleotide for chronic hepatitis B showcasing encouraging outcomes, especially in combination with pegylated interferon alfa. The trial evaluates the sequential regimen's efficacy in treating CHB infection, reducing hepatitis B surface antigen, and lowering virus DNA in the blood. Such developments hold a promising future for the vaccinations market in the forecast period.

Hepatitis B Vaccine Market Segmentation

Global "Hepatitis B Vaccine Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:

Market Breakup by Type

- Single Antigen
- Combination

Market Breakup by Age

- Pediatrics
- Adults

Market Breakup by End User

- Hospitals
- Clinics
- Vaccination Centres
- Others

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Hepatitis B Vaccine Market Overview

The World Health Organization estimates that the world population may suffer with 1.5 million new hepatitis B infections every year, as a result, the hepatitis B vaccine market demand has increased significantly. North America, particularly the United States, has dominated the market in the historical period. The market share can be accredited to the presence of key market players offering advanced vaccines. The region's well-established healthcare infrastructure and high awareness levels have further propelled market growth.

European market has also expanded with its robust healthcare system and proactive vaccination drives. The ongoing research and development activities by pharmaceutical companies, along with collaborations and partnerships among research institutions, continue to drive innovation in the region.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Going forward, Asia Pacific and Africa are poised to become pivotal centres for hepatitis B vaccine market share. These regions face a higher burden of hepatitis B infections, demanding high vaccination initiatives. Asia Pacific, being home to densely populated countries with emerging economies, is witnessing a surge in healthcare awareness and infrastructure development. The rising prevalence of hepatitis B in these regions amplifies the urgency for vaccination programs.

Hepatitis B Vaccine Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Merck & Co., Inc.
- Sanofi S.A.
- Dynavax Technologies Corporation
- GlaxoSmithKline plc.
- Pancea Biotech Ltd
- Beijing Tiantan Biological Products Co., Ltd.
- VBI Vaccines Inc.
- Emmy Vaccine Co. Ltd.
- Beijing Minhai Biological Technology Co., Ltd.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Hepatitis B Disease Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Hepatitis B Disease Epidemiology Analysis - 7MM

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1 7MM Epidemiology Scenario Overview (2018-2034)
- 5.2 United States Hepatitis B Disease Epidemiology Forecast (2018-2034)
- 5.3 EU-4 and United Kingdom Hepatitis B Disease Epidemiology Forecast (2018-2034)
 - 5.3.1 Germany Hepatitis B Disease Epidemiology Forecast (2018-2034)
 - 5.3.2 France Hepatitis B Disease Epidemiology Forecast (2018-2034)
 - 5.3.3 Italy Hepatitis B Disease Epidemiology Forecast (2018-2034)
 - 5.3.4 Spain Hepatitis B Disease Epidemiology Forecast (2018-2034)
 - 5.3.5 United Kingdom Hepatitis B Disease Epidemiology Forecast (2018-2034)
- 5.4 Japan Hepatitis B Disease Epidemiology Forecast (2018-2034)
- 6 Hepatitis B Vaccine Market Overview - 7MM
 - 6.1 Hepatitis B Vaccine Market Historical Value (2018-2024)
 - 6.2 Hepatitis B Vaccine Market Forecast Value (2025-2034)
- 7 Hepatitis B Vaccine Market Landscape - 7MM
 - 7.1 Hepatitis B Vaccine: Developers Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Hepatitis B Vaccine: Product Landscape
 - 7.2.1 Analysis by Type
 - 7.2.2 Analysis by Treatment Type
 - 7.2.3 Analysis by Diagnosis Method
- 8 Hepatitis B Vaccine Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Hepatitis B Vaccine Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Hepatitis B Vaccine Market Segmentation - 7MM
 - 11.1 Hepatitis B Vaccine Market by Type
 - 11.1.1 Market Overview
 - 11.1.2 Single Antigen
 - 11.1.3 Combination
 - 11.2 Hepatitis B Vaccine Market by Age
 - 11.2.1 Market Overview
 - 11.2.2 Pediatrics
 - 11.2.3 Adults
 - 11.3 Hepatitis B Vaccine Market by End User
 - 11.3.1 Market Overview
 - 11.3.2 Hospitals
 - 11.3.3 Clinics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.4 Vaccination Centres
- 11.3.5 Others
- 11.4 Hepatitis B Vaccine Market by Region
 - 11.4.1 Market Overview
 - 11.4.2 United States
 - 11.4.3 EU-4 and the United Kingdom
 - 11.4.3.1 Germany
 - 11.4.3.2 France
 - 11.4.3.3 Italy
 - 11.4.3.4 Spain
 - 11.4.3.5 United Kingdom
 - 11.4.4 Japan
- 12 United States Hepatitis B Vaccine Market
 - 12.1 Hepatitis B Vaccine Market Historical Value (2018-2024)
 - 12.2 Hepatitis B Vaccine Market Forecast Value (2025-2034)
 - 12.3 Hepatitis B Vaccine Market by Type
 - 12.4 Hepatitis B Vaccine Market by Treatment Type
- 13 EU-4 and United Kingdom Hepatitis B Vaccine Market
 - 13.1 Hepatitis B Vaccine Market Historical Value (2018-2024)
 - 13.2 Hepatitis B Vaccine Market Forecast Value (2025-2034)
 - 13.3 Germany Hepatitis B Vaccine Market Overview
 - 13.3.1 Hepatitis B Vaccine Market by Type
 - 13.3.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.4 France Hepatitis B Vaccine Market Overview
 - 13.4.1 Hepatitis B Vaccine Market by Type
 - 13.4.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.5 Italy Hepatitis B Vaccine Market Overview
 - 13.5.1 Hepatitis B Vaccine Market by Type
 - 13.5.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.6 Spain Hepatitis B Vaccine Market Overview
 - 13.6.1 Hepatitis B Vaccine Market by Type
 - 13.6.2 Hepatitis B Vaccine Market by Treatment Type
 - 13.7 United Kingdom Hepatitis B Vaccine Market Overview
 - 13.7.1 Hepatitis B Vaccine Market by Type
 - 13.7.2 Hepatitis B Vaccine Market by Treatment Type
- 14 Japan Hepatitis B Vaccine Market
 - 14.1 Hepatitis B Vaccine Market Historical Value (2018-2024)
 - 14.2 Hepatitis B Vaccine Market Forecast Value (2025-2034)
 - 14.3 Hepatitis B Vaccine Market by Type
 - 14.4 Hepatitis B Vaccine Market by Treatment Type
- 15 Regulatory Framework
 - 15.1 Regulatory Overview
 - 15.1.1 US FDA
 - 15.1.2 EU EMA
 - 15.1.3 INDIA CDSCO
 - 15.1.4 JAPAN PMDA
 - 15.1.5 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16 Clinical Trials Analysis
 - 16.1 Analysis by Trial Registration Year
 - 16.2 Analysis by Trial Status
 - 16.3 Analysis by Trial Phase
 - 16.4 Analysis by Therapeutic Area
 - 16.5 Analysis by Geography
- 17 Funding and Investment Analysis
 - 17.1 Analysis by Funding Instances
 - 17.2 Analysis by Type of Funding
 - 17.3 Analysis by Funding Amount
 - 17.4 Analysis by Leading Players
 - 17.5 Analysis by Leading Investors
 - 17.6 Analysis by Geography
- 18 Partnership and Collaborations Analysis
 - 18.1 Analysis by Partnership Instances
 - 18.2 Analysis by Type of Partnership
 - 18.3 Analysis by Leading Players
 - 18.4 Analysis by Geography
- 19 Supplier Landscape
 - 19.1 Merck & Co.,Inc.
 - 19.1.1 Financial Analysis
 - 19.1.2 Product Portfolio
 - 19.1.3 Demographic Reach and Achievements
 - 19.1.4 Mergers and Acquisitions
 - 19.1.5 Certifications
 - 19.2 Sanofi S.A.
 - 19.2.1 Financial Analysis
 - 19.2.2 Product Portfolio
 - 19.2.3 Demographic Reach and Achievements
 - 19.2.4 Mergers and Acquisitions
 - 19.2.5 Certifications
 - 19.3 Dynavax Technologies Corporation
 - 19.3.1 Financial Analysis
 - 19.3.2 Product Portfolio
 - 19.3.3 Demographic Reach and Achievements
 - 19.3.4 Mergers and Acquisitions
 - 19.3.5 Certifications
 - 19.4 GlaxoSmithKline plc.
 - 19.4.1 Financial Analysis
 - 19.4.2 Product Portfolio
 - 19.4.3 Demographic Reach and Achievements
 - 19.4.4 Mergers and Acquisitions
 - 19.4.5 Certifications
 - 19.5 Pancea Biotech Ltd
 - 19.5.1 Financial Analysis
 - 19.5.2 Product Portfolio
 - 19.5.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.5.4 Mergers and Acquisitions
- 19.5.5 Certifications
- 19.6 Beijing Tiantan Biological Products Co., Ltd.
 - 19.6.1 Financial Analysis
 - 19.6.2 Product Portfolio
 - 19.6.3 Demographic Reach and Achievements
 - 19.6.4 Mergers and Acquisitions
 - 19.6.5 Certifications
- 19.7 VBI Vaccines Inc.
 - 19.7.1 Financial Analysis
 - 19.7.2 Product Portfolio
 - 19.7.3 Demographic Reach and Achievements
 - 19.7.4 Mergers and Acquisitions
 - 19.7.5 Certifications
- 19.8 Emmy Vaccine Co.,Ltd.
 - 19.8.1 Financial Analysis
 - 19.8.2 Product Portfolio
 - 19.8.3 Demographic Reach and Achievements
 - 19.8.4 Mergers and Acquisitions
 - 19.8.5 Certifications
- 19.9 Beijing Minhai Biological Technology Co., Ltd.
 - 19.9.1 Financial Analysis
 - 19.9.2 Product Portfolio
 - 19.9.3 Demographic Reach and Achievements
 - 19.9.4 Mergers and Acquisitions
 - 19.9.5 Certifications
- 20 Hepatitis B Vaccine - Distribution Model (Additional Insight)
 - 20.1 Overview
 - 20.2 Potential Distributors
 - 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 22 Company Competitiveness Analysis (Additional Insight)
 - 22.1 Very Small Companies
 - 22.2 Small Companies
 - 22.3 Mid-Sized Companies
 - 22.4 Large Companies
 - 22.5 Very Large Companies
- 23 Payment Methods (Additional Insight)
 - 23.1 Government Funded
 - 23.2 Private Insurance
 - 23.3 Out-of-Pocket

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Hepatitis B Vaccine Market Size and Share Outlook - Forecast Trends and Growth
Analysis Report (2025-2034)**

Market Report | 2025-07-29 | 350 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4949.00
	Five User License	\$5949.00
	Corporate License	\$6969.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com